Use of antibodies against specific MHC-peptide complexes

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S388200, C530S388220, C530S389100, C530S866000, C530S868000

Reexamination Certificate

active

07320873

ABSTRACT:
The invention describes a method to diagnose the autoimmune disease activity by detecting the presence of an autoimmune specific MHC-peptide complex in a patient suffering from an autoimmune disease. The MHC-peptide complex is associated with rheumatoid arthritis. Monoclonals antibodies to be used for this method are also described. The antibodies can also be used for therapeutic purposes.

REFERENCES:
patent: 6020170 (2000-02-01), Steenbakkers
patent: 488470 (1992-06-01), None
patent: 95 01995 (1995-01-01), None
patent: 95 02188 (1995-01-01), None
Wicks, I et al (Ann. Rheum. Dis. [1997] 56:135-139.
Tisch, R et al. Proc. Nat. Acad. Sci. (USA). [1994] 91:437-438.
Harvey S et al: “Chondrex: New Marker of Joint Disease”; Clinical Chemistry, American Association for Clinical Chemistry, Winston, US, vol. 44, No. 3, Mar. 1998, pp. 509-516.
Verheijden G F M et al: “Human Cartilage Glycoprotein-39 as a Candidate Autoantigen in Rheumatoid Arthritis”; Arthritis and Rheumatism, Lippincott, Philadelphia, US, vol. 40, No. 6, Jun. 1997, pp. 1115-1125.
Porgador A et al: “Localization Quantitation, and in SITU Detection of Specific Peptide-MHC Class I Complexes using a Monoclonal Antibody”; Immunity, Cell Press, US, vol. 6, No. 6, Jun. 1997, pp. 715-726.
Adang et al., “Case Histories of Peptidomimetics: Progression from Peptides to Drugs,”Recl. Trav. Chim. Pays-Bas113 (1994) 63-78.
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,”Science274 (1996) 94-96.
Baeten et al, “Detection of Major Histocompatibility Complex/Human Cartilage gp-39 Complexes in Rheumatoid Arthritis Synovitis as a Specific and Independent Histologic Marker,”Arthritis Rheum.50 (2004) 444-451.
Baeten et al., “Human Cartilage gp-39+, CD16+ Monocytes in Peripheral Blood and Synovium,”Arthritis Rheum43 (2000) 1233-1243.
Cope et al., “T Cell Responses to a Human Cartilage Autoantigen in the Context of Rheumatoid Arthritis-Associated and Nonassociated HIA-DR4 Alleles,”Arthritis Rheum.42 (1999) 1497-1507.
Fields et al., “Solid Phase Peptide Synthesis Utilizing 9-fluorenylmethoxycarbonyl amino acids,”Int. J. Peptide Protein Res.35 (1990) 161-214.
Gütgemann et al., “Induction of Rapid T Cell Activation and Tolerance by Systemic Presentation of an Orally Administered Antigen,”Immunity8 (1998) 667-673.
Jones et al., “Replacing the Complementarity-Determining Regions In a Human Antibody With those from a Mouse,”Nature321 (1986) 522-525.
Joosten et al., “Induction of Tolerance With Intranasal Administration of Human Cartilage gp-39 In DBA/1 Mice,”Arthritis Rheum.43, (2000) 645-655.
Köhler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature256 (1975) 495-497.
Kotzin et al., “Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis,”PNAS97 (2000) 291-296.
Lebowitz et al., “Soluble, High-Affinity Dimers of T-Cell Receptors and Class II Major Histocompatibility Complexes: BIochemical Probes for Analysis and Modulation of Immune Responses,”Cellular Immunology192 (1999) 175-184.
Lipman et al., “Rapid and Sensitive Protein Similarity Searches,”Science227, (1985) 1435-1441.
Merrifield, “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptlde,”J. Amer. Chem. Soc.85 (1963) 2149-2154.
Powell et al., “Peptide Stability in Drug Development: A Comparison of Peptide Reactivity in Different Biological Media,”J. Pharm. Sci.81 (1992) 731-735.
Simon et al., “Peptoids: A modular approach to drug discovery,”PNAS89 (1992) 9367-9371.
Steenbakkers et al., “A New Approach to the Generation of Human or Murine Antibody Producing Hybridomas,”J. Immunol. Methods152 (1992) 69-77.
Steenbakkers et al., “Efficient Generation of Monocional Antibodies from Preselected Antigen-Specific B Cells,”Molecular Biology Reports19 (1994) 125-134.
Van Duijn et al., “High Yields of Specific Hybridomas Obtained by Electrofusion of Murine Lymphocytes Immunized in Vivo or in Vitro,”Exp. Cell Research183 (1989) 463-472.
Nag et al., “Purified β-Chain of MHC Class II Binds to CD4 Molecules on Transfected HeLa Cells,”J. Immunol.150 (1993) 1358-1364.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Use of antibodies against specific MHC-peptide complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of antibodies against specific MHC-peptide complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antibodies against specific MHC-peptide complexes will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2780108

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.